Your browser doesn't support javascript.
loading
Publisher Correction: UTX-mediated enhancer and chromatin remodeling suppresses myeloid leukemogenesis through noncatalytic inverse regulation of ETS and GATA programs.
Gozdecka, Malgorzata; Meduri, Eshwar; Mazan, Milena; Tzelepis, Konstantinos; Dudek, Monika; Knights, Andrew J; Pardo, Mercedes; Yu, Lu; Choudhary, Jyoti S; Metzakopian, Emmanouil; Iyer, Vivek; Yun, Haiyang; Park, Naomi; Varela, Ignacio; Bautista, Ruben; Collord, Grace; Dovey, Oliver; Garyfallos, Dimitrios A; De Braekeleer, Etienne; Kondo, Saki; Cooper, Jonathan; Göttgens, Berthold; Bullinger, Lars; Northcott, Paul A; Adams, David; Vassiliou, George S; Huntly, Brian J P.
Afiliação
  • Gozdecka M; Haematological Cancer Genetics, Wellcome Trust Sanger Institute, Hinxton, UK.
  • Meduri E; Wellcome Trust-MRC Stem Cell Institute, Cambridge Biomedical Campus, University of Cambridge, Cambridge, UK.
  • Mazan M; Wellcome Trust-MRC Stem Cell Institute, Cambridge Biomedical Campus, University of Cambridge, Cambridge, UK.
  • Tzelepis K; Haematological Cancer Genetics, Wellcome Trust Sanger Institute, Hinxton, UK.
  • Dudek M; Wellcome Trust-MRC Stem Cell Institute, Cambridge Biomedical Campus, University of Cambridge, Cambridge, UK.
  • Knights AJ; Haematological Cancer Genetics, Wellcome Trust Sanger Institute, Hinxton, UK.
  • Pardo M; Haematological Cancer Genetics, Wellcome Trust Sanger Institute, Hinxton, UK.
  • Yu L; Genomics of Gene Regulation, Wellcome Trust Sanger Institute, Hinxton, UK.
  • Choudhary JS; Proteomic Mass Spectrometry, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, UK.
  • Metzakopian E; Proteomic Mass Spectrometry, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, UK.
  • Iyer V; Proteomic Mass Spectrometry, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, UK.
  • Yun H; Mouse Genomics, Wellcome Trust Sanger Institute, Hinxton, UK.
  • Park N; Experimental Cancer Genetics, Wellcome Trust Sanger Institute, Hinxton, UK.
  • Varela I; Wellcome Trust-MRC Stem Cell Institute, Cambridge Biomedical Campus, University of Cambridge, Cambridge, UK.
  • Bautista R; Sequencing Research Group, Wellcome Trust Sanger Institute, Cambridge, UK.
  • Collord G; Instituto de Biomedicina y Biotecnología de Cantabria (CSIC-UC-Sodercan), Departamento de Biología Molecular, Universidad de Cantabria, Santander, Spain.
  • Dovey O; New Pipeline Group, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, UK.
  • Garyfallos DA; Haematological Cancer Genetics, Wellcome Trust Sanger Institute, Hinxton, UK.
  • De Braekeleer E; Haematological Cancer Genetics, Wellcome Trust Sanger Institute, Hinxton, UK.
  • Kondo S; Haematological Cancer Genetics, Wellcome Trust Sanger Institute, Hinxton, UK.
  • Cooper J; Haematological Cancer Genetics, Wellcome Trust Sanger Institute, Hinxton, UK.
  • Göttgens B; Laboratory of Molecular Genetics, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
  • Bullinger L; Haematological Cancer Genetics, Wellcome Trust Sanger Institute, Hinxton, UK.
  • Northcott PA; Cambridge Institute for Medical Research and Wellcome Trust-Medical Research Council, Stem Cell Institute and Department of Haematology, University of Cambridge, Cambridge, UK.
  • Adams D; Department of Internal Medicine III, Ulm University Medical Centre, Ulm, Germany.
  • Vassiliou GS; Medical Department, Division of Hematology, Oncology and Tumour Immunology, Charité Universitätsmedizin Berlin, Berlin, Germany.
  • Huntly BJP; Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Nat Genet ; 54(7): 1062, 2022 Jul.
Article em En | MEDLINE | ID: mdl-35701672
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article